Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma. Issue 4 (11th January 2020)

• Record Type: Journal Article
• Authors: Marr, Kristin; Ronsley, Rebecca; Nadel, Helen; Douglas, Kate; Gershony, Sharon; Strahlendorf, Caron; Davis, Jeffrey H.; Deyell, Rebecca J.
• Is Part Of: Pediatric blood & cancer. Volume 67:Issue 4(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-01-11
• Subjects: autologous stem cell transplantation -- Hodgkin lymphoma -- IGEV -- pediatric; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.28167
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: We describe 12 pediatric patients (8‐16 years) with primary refractory ( N = 6) or first relapse ( N = 6) Hodgkin lymphoma (HL) treated with ifosfamide, gemcitabine, and vinorelbine (IGEV). The overall response rate to IGEV was 100%, with seven (58%) complete responses (CR) and five (42%) partial responses. Successful CD34 + stem cell mobilization was achieved in all patients. Following subsequent autologous stem cell transplantation, 10 patients (83%) achieved CR. At a median follow‐up of 71 months, 11 patients had no evidence of disease. Five‐year second event‐free survival and overall survival were 83% ± 11.0% and 90.0% ± 9.5%, respectively. IGEV is an effective salvage regimen for children with relapsed/refractory HL.